Ipca Laboratories Share Price Live
Live Ipca Laboratories Share Price Chart
Ipca Laboratories Performance
Days Range
| Previous Close | ₹1,447.70 |
|---|---|
| Open | ₹1,430 |
| Volume | 1,96,937 |
| Day's Range | ₹1,395.00 - ₹1,469.90 |
|---|---|
| 52W Range | ₹1,168.20 - ₹1,755.90 |
| Market Cap | ₹36,774.43 Cr |
Ipca Laboratories Fundamentals
| ROCE(TTM) | 17.89 |
|---|---|
| P/E Ratio (TTM) | 43.08 |
| P/B Ratio | 4.95 |
| Industry P/E | 32.93 |
| Debt to Equity | 0.17 |
| ROE | 13.33 |
| EPS (TTM) | 39.02 |
| Dividend Yield | 0.28 |
| Book Value | 292.74 |
| Face Value | 1 |
| ROCE(TTM) | 17.89 |
|---|---|
| P/E Ratio (TTM) | 43.08 |
| P/B Ratio | 4.95 |
| Industry P/E | 32.93 |
| Debt to Equity | 0.17 |
| ROE | 13.33 |
|---|---|
| EPS (TTM) | 39.02 |
| Dividend Yield | 0.28 |
| Book Value | 292.74 |
| Face Value | 1 |
Ipca Laboratories Financials
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | |
|---|---|---|---|---|
| Net Sales | 2,245.37 | 2,246.69 | 2,308.85 | 2,556.50 |
| Expenses | 1,880.75 | 1,917.95 | 1,992.49 | 2,114.91 |
| Profit before tax | 367.92 | 128.00 | 330.51 | 391.58 |
| Operating Profit | 277.33 | 65.78 | 234.42 | 283.50 |
| Net Profit | 277.33 | 65.78 | 234.42 | 283.50 |
| ESP in Rs | 9.78 | 10.99 | 9.19 | 13.43 |
Ipca Laboratories Shareholding Pattern
| Held by | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|
| Promoters | 46.3% | 44.72% | 44.72% | 44.72% | 44.72% |
| Flls | 10.83% | 11.07% | 10.76% | 10.67% | 10.43% |
| Dlls | 34.23% | 35.68% | 36.06% | 36.2% | 36.77% |
| Public | 8.64% | 8.53% | 8.46% | 8.41% | 8.07% |
About Ipca Laboratories
Ipca Laboratories is involved in the manufacturing and marketing of pharmaceuticals. The company was incorporated as `The Indian Pharmaceutical Combine Association Limited' in 1949. The company has changed its name several times. At first, it changed its name to `Ipca Laboratories Ltd. in 1964. Two years later, in 1966, it changed its name to Ipca Laboratories Private Limited. In 1988, it again changed its name to Ipca Laboratories Ltd in 1988.
The company established a modern plant at Athal, Silvassa, for the manufacturing of pharmaceutical formulations in 1994. It launched a new domestic marketing division, ACTIVA, dedicated to Rheumatology Care in 2003. Ipca continued its inorganic growth in 2005 by acquiring the Cardiac brand ISORDIL from Wyeth Limited. In the same year, it finished its merger with Innotech Pharma Limited.
In 2008, Ipca Laboratories received US FDA approval for Propranolol Hydrochloride Tablets. Ipca Laboratories received approval from the UK Medicines and Healthcare Products Regulatory Agency for its 4th manufacturing unit at a Special Economic Zone in Indore for good manufacturing practices under the regulator in 2011.
The company finished the acquisition of a High Potency Oral Solid Dosage formulations manufacturing unit situated at Pithampur near Indore in 2014. It acquired a 100% stake in Ramdev Chemical Private Limited in 2019. In 2022, the company commenced a new green field manufacturing unit being set up at Dewas (Madhya Pradesh).
Business Segments
- APIs: The company manufactures 80+ APIs at 12 production facilities, accounting for nearly 25% of its turnover. The company’s leadership extends across the manufacturing of Atenolol (anti-hypertensive) and Chloroquine Phosphate (anti-malarial).
- Formulations: Under this segment, it manufactures 350+ formulations in almost every dosage form, with 4 of its branded formulations. It is a leader in Pain, Rheumatology, Antimalarials and Haircare therapies with a steadily growing portfolio.
- Global Business: The company has a rich presence across the UK, the USA and Russia. It operates its USA business through Bayshore Pharmaceuticals LLC.
- Ipca Laboratories (U.K.) Ltd: It is a wholly-owned subsidiary which was incorporated to apply for and obtain product registrations in the United Kingdom.
- Ipca Pharmaceuticals, Inc. USA: It is a wholly-owned subsidiary that coordinates the development and registration of formulations developed by Ipcs in the USA as well as the distribution of Active Pharmaceutical Ingredients (APIs) manufactured in the US market.
Key Personnel
Ajit Kumar Jain, Managing Director & CFO Mr A. K. Jain is a Chartered Accountant and a Science Graduate and has been with the company since 1981. He joined the company as a financial controller. He holds a rich experience of over 30, including 29 years in the pharmaceutical industry. Mr. Jain was first appointed to the Board as an Executive Director in 1994.Corporate Actions
The company has no history of bonus issues, stock splits and other corporate actions.Parent Organisation
Indian Private
Managing Director
Premchand Godha
Founded
1949
NSE Symbol
IPCALAB
Top Mutual Funds Invested in Ipca Laboratories Share
Top Mutual Funds Invested in Ipca Laboratories Share
Peer Comparison
Peer Comparison
| Stocks | LTP (₹) | Market Cap (cr) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | 1,775.3 -20.90 (-1.16%) | ₹4,30,752.61 | 1,548.0 - 1,910.0 |
| Divis Laboratories Ltd | 6,296.5 -32.00 (-0.51%) | ₹1,67,997.81 | 4,955.0 - 7,071.5 |
| Torrent Pharmaceuticals Ltd | 3,766.0 6.00 (0.16%) | ₹1,27,180.39 | 2,886.45 - 3,882.2 |
| Cipla Ltd | 1,491.9 -5.70 (-0.38%) | ₹1,20,959.70 | 1,335.0 - 1,673.0 |
| Dr Reddys Laboratories Ltd | 1,248.3 -18.20 (-1.44%) | ₹1,05,759.02 | 1,020.0 - 1,405.9 |
| Lupin Ltd | 2,051.3 -19.40 (-0.94%) | ₹94,611.43 | 1,795.2 - 2,402.9 |
Popular stocks
Ipca Laboratories Ltd FAQs
What is the share price of Ipca Laboratories Ltd (IPCALAB) shares?
Ipca Laboratories Ltd (IPCALAB) share price as of December 9, 2025, on NSE is Rs 1451 (NSE) and Rs 1451 (BSE) on BSE.
Can I buy Ipca Laboratories Ltd (IPCALAB) from Angel One?
Yes, You can buy Ipca Laboratories Ltd (IPCALAB) shares by opening a Demat account with Angel One.
How do I buy Ipca Laboratories Ltd (IPCALAB) from Angel One?
Ipca Laboratories Ltd (IPCALAB) share can be bought through the following modes:
1. Direct investment: You can buy Ipca Laboratories Ltd (IPCALAB) shares by opening a Demat account with Angel One.
2. Indirect investment: The indirect method involves investing through ETFs and Mutual Funds that offer exposure to Ipca Laboratories Ltd (IPCALAB) shares.
1. Direct investment: You can buy Ipca Laboratories Ltd (IPCALAB) shares by opening a Demat account with Angel One.
2. Indirect investment: The indirect method involves investing through ETFs and Mutual Funds that offer exposure to Ipca Laboratories Ltd (IPCALAB) shares.
What is the main business of IPCA Laboratories?
The main business of IPCA Laboratories is to produce and sell pharmaceutical products and drugs, including formulations, active pharmaceutical ingredients (APIs), and drug intermediates.
Who are the promoters of IPCA Laboratories?
Some of the promoters of IPCA Laboratories are Kaygee Investments Private Limited, Kaygee Laboratories Private Limited, Chandurkar Investments Private Limited, Paschim Chemicals Pvt Ltd, Premchand Godha, Usha M Chandurkar, Sameer M Chandurkar, Pranay Godh, Prashant Godha, and Usha Premchand Godha.
What are the Subsidiaries that comes under IPCA Laboratories?
Some of the subsidiaries that come under IPCA Laboratories include Ipca Pharmaceuticals, Inc., Ipca Laboratories (UK) Ltd., Ipca Pharma (Australia) Pty Ltd., Ipca Pharma Nigeria Ltd., Ipca Pharmaceuticals Ltd. SA de CV, Tonira Exports Ltd., and Ramdev Chemical Pvt. Ltd.
